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Our objective was to investigate the relationship between phenytoin bioavailability, enteral feeding and serum albumin levels in
patients admitted to neurology/neurosurgery ITU, via case studies of three patients.
The research was performed at the Walton centre for Neurology and Neurosurgery NHS Trust, Liverpool, England, and our
subjects consisted of three cases admitted to ITU (1 status epilepticus, 1 post-trauma and 1 post-subarachnoid haemorrhage
(SAH)).
Phenytoin levels were assessed in relation to the type of feeding and serum albumin levels.
We found evidence of a complex relationship between phenytoin levels, enteral feeding and serum albumin in patients in the
neuro ITU setting.
We conclude that, in this setting the patient’s phenytoin needs to be closely monitored and treated aggressively to maintain
therapeutic levels. They should also be followed up during rehabilitation to avoid toxicity.
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INTRODUCTION
Patients admitted to our neurology/neurosurgery ITU
are frequently unconscious or sedated, and hence,
have to be enterally fed. It is quite common for these
patients to develop seizures post-operatively or post-
trauma, or indeed they may have status epilepticus.
Similarly, 3.5% of all admissions to general ITU with
primarily a non-neurological diagnosis will develop
seizures1. For these patients, their seizures are po-
tentially life threatening. The mortality rate for all
patients who go into status epilepticus is 22% (3%
for children and 26% for adults)2. Therefore, the ad-
ministration of therapeutic doses of a recognized an-
ticonvulsant is of paramount importance. Phenytoin is
considered the agent of first choice for post-operative
seizures, post-trauma seizures and for status epilep-
ticus because therapeutic levels and response can be
achieved quickly.
Phenytoin pharmacokinetics are quite problematic
even in an ideal setting. It has a half-life that can vary
from 13 to 46 hours and hence it takes up to 2 weeks to
reach steady state3. Phenytoin is highly protein bound
and hence levels can be severely affected by hypoal-
buminaemia or renal failure4. Its metabolism can also
be altered by hepatic impairment or indeed other drugs
that are similarly metabolized, notably other anticon-
vulsants5. The additional problem which arises is that
phenytoin is known to interact with most forms of en-
teral feed5, leading to erratic bioavailability and often
substantial reductions in total serum phenytoin con-
centrations.
MATERIALS AND METHODS
On recognizing this problem, we consulted the litera-
ture, Parke-Davis Pharmaceuticals and consultants in
our own unit and decided on a policy of stopping en-
teral feeding 2 hours before and after administration
of oral or nasogastric phenytoin. This policy has now
been in place for 3 years. However, review of several
cases reveals that this policy has not solved the prob-
lem. Indeed, even the administration of IV phenytoin
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Fig. 1: (JL) Male 61 years old.
Fig. 2: (PW) Female 49 years old.
may be ineffective§ .
We reviewed three cases of such patients retrospec-
tively to gain some insight into the problem. One post-
trauma (JL), one post-SAH (PW) and once with sta-
tus epilepticus (SW). This review entailed document-
ing the phenytoin doses given (regular daily doses and
boluses), the serum phenytoin levels and whether the
patient was concurrently fed via a NG tube, intra-
venously or orally; axes labels Nasogastric (ng)/total
paventeral nutrition (tpn) and oral, respectively, in the
figures. These were then plotted graphically to high-
light the relationship between all three factors¶ .
RESULTS
Case study 1: (JL) Male 61 years old
JL was a pedal cyclist involved in a RTA and suffered
a right subdural haematoma with midline shift and
frontal lobe contusions. On admission to hospital he
had one generalized tonic–clonic seizure (GTCS), and
was commenced on phenytoin. He was paralysed and
sedated soon after this and had no further recorded
seizures. He never regained consciousness and died
on day 15.
JL was given only i.v. phenytoin throughout his ad-
mission. There is a noticeable decline in the serum
level which was partially altered by a 50% increase
in the dose (see Fig. 1). He did receive an initial load-
ing of 1000 mg which would have achieved a thera-
peutic level (>40 mcg mol−1 L) early on. It is also
noticeable that the suppression of the serum albumin
is progressive throughout and this in turn lowers the
total phenytoin because the albumin binding capacity
has been reduced.
Case study 2: (PW) Female 49 years old
PW was transferred to W.C.N.N. with an extensive
SAH on 24/6/98. She was thought to have possibly had
a seizure on 4/7/98 but was not loaded with phenytoin
§
The therapeutic range of serum phenytoin is considered to fall between 40 and 80 µ mol−1L.
¶
To join two points using the excel program we had to generate all points in between.
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Fig. 3: (SW) Female 19 years old.
until 30/7/98 (day 1) when she had a definite GTCS.
She had a P.E. on 28/10/98 and died.
PW follows a similar but more prolonged pattern
to the previous case. A large initial loading dose plus
regular daily doses of 300 mg failed to maintain a
therapeutic level and even when the daily dose was
increased to 500 mg it seemed to make little impres-
sion on the serum level (see Fig. 2). PW died one
month after day 55 and no further levels were taken.
Hence, no comparisons to oral feeding can be made.
However, the mirroring of phenytoin levels against
serum albumin levels is quite remarkable. The total
serum phenytoin rises and falls with the fluctuations
in serum albumin.
Case study 3: (SW) Female 19 years old
SW was a patient with status epilepticus who was also
monitored closely, and treated aggressively with sev-
eral i.v. boluses and high daily doses (see Fig. 3). This
regimen was indeed successful at maintaining the re-
quired level but as solid food was commenced the
phenytoin levels climbed into the toxic range and she
was symptomatic. SW also had low serum albumin
levels until dietician intervention at around day seven.
As her nutrition improved, it had the gradual effect
of helping to raise her albumin. This may have con-
tributed to the rise in total serum phenytoin.
DISCUSSION
On studying these examples a consistent pattern can be
seen to be emerging. After admission and loading with
phenytoin the initial level drops dramatically within
days. This coincides with commencement of concur-
rent nasogastric feeding and observably low serum al-
bumin levels.
Significantly increasing the daily dose of phenytoin,
whether i.v. or oral, has little impact on levels. How-
ever, vigilant monitoring and administration of appro-
priate boluses produces total phenytoin levels within
the target range. It should be borne in mind that steady
state for serum phenytoin can take up to 2 weeks to
achieve but with these patients we are often not af-
forded the luxury of this time.
Whether or not seizures are suppressed by levels
within the target range, another problem occurs once
solid feeding has been recommenced because pheny-
toin toxicity on the same regular dose can occur in-
conspicuously. This is a particular problem once the
patient leaves the ITU setting.
Phenytoin is usually about 90% protein bound6.
However, it may be the case that due to the dy-
namic haematological conditions, the patient may
have higher levels of ‘free’ phenytoin even though
their ‘total’ phenytoin level is considered subthera-
peutic. It may be more appropriate to monitor ‘free’
phenytoin levels.
This is a difficult area to study owing to the limi-
tations placed upon investigators by the nature of the
subjects being examined. They are acutely ill, may be
suffering from multiple complicating factors (includ-
ing neurological ones), and hence entering them into
a controlled clinical trial would be ethically question-
able. Therefore, the reporting of this problem is anec-
dotal. These three cases have been selected because
they are good examples of a problem which is seen
consistently within our unit.
There are conflicting views7, 8 regarding the interac-
tion between phenytoin and NG feeding, some in sup-
port of this interaction7, and some which refute it as
a myth8. Assuming an interaction exists, there are two
possible explanations for this interaction.
Firstly, it could be due to poor absorption of the
phenytoin from the gastro-intestinal tract (GIT). Ran-
dall and Tett9 suggest a physicochemical reaction pro-
ducing a nonabsorbable complex between the pheny-
toin and the enteral feed which may be hampering
absorption, but this is refuted by Krueger et al.10.
They suggest it may have more to do with the en-
268 D. Kitchen and D. Smith
teral feed having an adverse effect on the motility and
absorptive capabilities of the GIT in respect to the
phenytoin but further research is necessary. Secondly
suppression of phenytoin levels could be the result
of increased metabolic clearance due to changes in
protein binding, induction of hepatic metabolism or
stress related transient increases in hepatic function9
or combinations of these factors11.
CONCLUSIONS
The ITU patient with seizures who is receiving pheny-
toin and being enterally fed will fall into one of the
following scenarios:-
(1) They have low serum phenytoin levels but
no further seizures. They should be observed
closely monitoring both phenytoin and serum
albumin.
(2) They have low phenytoin levels and poorly
controlled seizures. Levels should be measured
daily and bolus (es) given to maintain target
levels.
(3) The patient is adequately controlled with pheny-
toin levels in the target range.
Irrespective of which category they fall into, when
the patient is changed back from enteral to normal
food they should again be monitored closely for some
time for their phenytoin levels can easily become
toxic. They are especially at risk once they have left
the ITU setting.
Whilst the research is obviously needed in this area,
phenytoin remains, pharmacokinetically, a dynamic
drug which suffers a complexity of interactions with
other drugs and feeds5. Clinicians should be moni-
toring the target levels not the dose being adminis-
tered nor the seizure free status of the patient as the
sole methods of monitoring phenytoin efficacy and
toxicity.
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